Group 1 - The company held its 24th temporary board meeting on December 25, 2025, where several resolutions were passed unanimously by the board members [1][2][4] - The company approved a proposal to postpone the investment project related to the development of tumor marker diagnostic reagents, extending the timeline to December 2026 [35][41] - The company appointed Mr. Zhang Yu as the co-president to enhance operational management efficiency in response to market challenges [2][9] - The company appointed Mr. Li Xu as the secretary of the board, ensuring compliance with relevant laws and regulations [5][10] Group 2 - The company plans to use up to RMB 1.2 billion of temporarily idle raised funds for cash management and up to RMB 600 million of idle self-owned funds for entrusted wealth management [22][24] - The company has a balance of RMB 159.87 million in raised funds as of December 15, 2025, with some funds temporarily idle due to project timelines [24][36] - The company will invest in low-risk, liquid principal-protected products and ensure that these investments do not affect the normal operations of the company [25][32] Group 3 - The company signed a termination agreement with the University of Chinese Academy of Sciences regarding the "Zhongyuan Xiehe Life Medicine Award," ceasing further donations after a total of RMB 7.8 million was contributed [11][12][19] - The termination of the donation agreement will not significantly impact the company's operations or financial status, as it seeks new partners for the award [19][41]

Core Viewpoint - The company announced a delay in the clinical trial progress of its "Tumor Biomarker Diagnostic Reagent Development Project" due to public health events and new clinical trial guidelines, pushing the project completion date to December 2026 [1] Investment Project Details - The planned investment amount for the project is 60 million yuan, funded by raised matching funds [1] - The project focuses on the development of diagnostic kits for gene mutation testing, specifically targeting genes such as EGFR, KRAS, BRAF, NRAS, ERBB2, and PIK3CA, as well as a multi-gene mutation testing kit for circulating tumor DNA [1] Impact of Delay - The delay does not involve changes to the implementation entity, method, or investment amount, and it will not affect the direction of the raised funds [1] - The company asserts that the delay will not have a substantial impact on its normal operations [1]